Reglagene is a ground-breaking therapeutics company designing small-molecule treatments that will pass through the blood-brain barrier. With brain cancer survival rates at barely a year using current treatment methods, Reglagene's new medicine is expected to revolutionize the care of high-grade gliomas, metastatic brain cancers and neurological disorders. The firm's core expertise lies in the design and development of brain-penetrant medicines, allowing them to confront these diseases head-on.